Reported 3 days ago
In its recent investor letter, Vltava Fund highlighted Novo Nordisk A/S (NYSE:NVO) as a major player in the treatment of diabetes and obesity, noting its historical growth through insulin production and its dominance in the market. Despite a recent decline in share value, the company maintains a strong integrated production model and faces limited competition, primarily from Eli Lilly. With significant barriers to entry in the industry, Novo Nordisk is viewed as a promising investment, although some analysts suggest that other sectors, like AI, may offer higher potential returns.
Source: YAHOO